THE FUTURE OF BRACHYTHERAPY IS A PARTNERSHIP

MYRIAD MEDICAL & C4 IMAGING INTRODUCE THE *FIRST* POSITIVE SIGNAL LDR MRI MARKER

BOTH A SEED SPACER & A MARKER

The SIRIUS™ MRI positive-signal LDR marker replaces the spacer in stranded brachytherapy seeds, independent of isotope selection.

The SIRIUS™ marker allows MRI visualization of each strand for post-implant dosimetry evaluations and provides an accurate reference to fuse MRI with CT and ultrasound images for more precise targeting of the prostate.

- No impact on treatment planning and delivery — SIRIUS™ simply replaces seed spacers
  - Sealed biocompatible polymer capsule containing C4, a unique MRI agent.
  - Anisotropy measurements taken when SIRIUS™ was attached to Iodine 125 seeds were equivalent to standard TG43 parameters.[1]
  - SIRIUS™ does not alter Monte Carlo-calculated radiation treatment delivery when compared to standard seed spacers.[2]
- Post-implant seed localization with MRI alone
  - SIRIUS™ has been demonstrated to be visible as T1W and T2W signals and can positively identify the location of implanted radioactive seeds.
  - The superior image quality of MRI could improve the accuracy of prostate contouring.
  - If seeds could be readily localized with MRI, it could reveal the true relationship of radiation dose to the prostate and critical dose-limiting structures.

SIRIUS MRI MARKER

REPRESENTED IN THE U.S. BY

myriadmedical

BRACHYTHERAPY IS A STANDARD OPTION FOR THE CURATIVE TREATMENT OF PROSTATE CANCER.

- The inability of standard imaging options to clearly visualize soft tissue can complicate accurate assessment of dose delivered by implanted seeds.
- The efficacy of MRI for evaluating soft tissues after seed implantation has been well described.[3]
- However, all seeds have a titanium shell, which under MRI appears as a signal void that cannot be easily distinguished from needle tracks or blood vessels.
- A study estimating prostate gland volumes highlighted significant inter-observer differences when using post-implant CT scans.[4]



SIRUS™ marker is compatible with Iodine, Palladium and Cesium stranded seeds.

To place an order, please contact us to coordinate with your existing seed supplier.

EMAIL: sales@myriadoncology.com PHONE: +1 (888) 872-7940

Customer Service Hours 8:00 A.M. to 6:00 P.M. EST. Monday - Friday

Myriad Medical, LLC
2202 N. West Shore Blvd.
Suite 200
Tampa, FL 33607
FAX: +1 (904) 240-4469
LB-061019-61

REFERENCES
1. Frank SJ, Tailor RC, Kudchadker RJ, et al. Anisotropy characterization of I-125 seed with attached encapsulated cobalt chloride complex contrast agent markers for MRIbased prostate brachytherapy. Med Dosim. 2011; 36(2): 200-205.
2. Melhus CS, Mourtada F, Mikell JK, et al. Dosimetric Influence of Brachytherapy Seed Spacers. Brachytherapy. 2011; 10S: 94-95.
3. McLaughlin PW, Troyer S, Berri S, et al. Functional anatomy of the prostate: implications for treatment planning. Int J Radiat Oncol Biol Phys. 2005; 63(2): 479-91.
4. Lee WR, Roach M 3rd, Michalski J, et al. Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. Int J Radiat Oncol Biol Phys. 2002; 54(2): 457-61.

myriadmedical